BioSpace News Archive

Project to help each entity reach bold carbon-reduction goals U.S. Department of Energy to fund year-long study

Specialty cancer diagnostics company Precipio, Inc. has entered into an agreement with a major US-based oncology distributor to offer Precipio’s HemeScreen POL program to its independent community oncology practices nationwide.

Company innovates by incorporating key features of the new Apple Watch to improve and extend outcomes of PneumoBlast™ as a potential new COVID-19 therapy

Hoth Therapeutics, Inc. (NASDAQ: HOTH ), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to commence the first cohort of the Phase 1b clinical trial of BioLexa Lotion for the treatment of mild to moderate atopic dermatitis in Australia.

Largest grant in Shepherd Center’s history will support the specialized rehabilitation hospital’s most significant expansion in 45 years

Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine Data from 43,448 participants, half of whom received BNT162b2 and half of whom received placebo, showed that the vaccine candidate was well tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection 7 days or more after the second dose Vaccine efficacy o

As a leading provider in teleradiology Rapid Radiology has received the golden seal of approval® presented by The Joint Commission Rapid Radiology has been awarded Re-accreditation from The Joint Commission

Summus Medical Laser, the leader in Class IV Therapeutic Lasers, today announced the company has been selected as a Top 5 Innovator by Guided Solutions with their international debut of The Horizon Laser System at COMPAMED/MEDICA 2020.

- For nearly 11 months, we have all been learning to live and function in a state of uncertainty, adjusting to a “new normal” as the COVID-19 pandemic has drastically affected the way most of us live, and has also tragically claimed

Partnership Seeks to Lower Barriers to Evidence-Based Molecular Oncology Care by Extending Trapelo’s Decision Support Solutions Through Concert’s Network of Laboratories and Health Plans